Eli Lilly's stock surged 3.9% after an outstanding Q3 earnings report, surpassing analysts' expectations with $7.02 per share and $17.6 billion in sales. The company raised its yearly guidance, signaling strong growth potential.
Eli Lilly's third-quarter results exceeded estimates, driven by strong demand for Zepbound and Mounjaro. The company raised its revenue forecast, fueling a 5% rise in shares. Discover how Eli Lilly is maintaining its lead in the competitive obesity drug market.
In a candid discussion, celebrities share their experiences with Ozempic and other weight loss medications, revealing surprising truths, struggles, and the societal pressures surrounding body image.
Eli Lilly announces a dramatic price increase for its diabetes medication Mounjaro in the UK, raising the monthly cost from £122 to £330. This change affects private buyers but not NHS prescriptions. Learn more about the implications!
Recent studies suggest a link between GLP-1 medications like Ozempic and vision loss. Learn about the risks and what you need to know if you're using these popular diabetes drugs.
Are you one of the many Americans using GLP-1 drugs like Ozempic or Wegovy? Discover essential lifestyle tips to prevent nutrient deficiencies and muscle loss while maximizing your weight loss results!
From dramatic weight loss transformations to cautionary tales, celebrities are opening up about their experiences with Ozempic and Mounjaro. Discover their honest opinions and the health risks they faced!
In a groundbreaking clinical trial, Mounjaro proves to be nearly 50% more effective than Ozempic. This article explores the implications of this major breakthrough in weight loss treatments.
A landmark study reveals that weight-loss injections may significantly reduce the risk of obesity-related cancers, potentially transforming preventive medicine. The findings suggest that GLP-1 receptor agonists could halve cancer risk, prompting calls for further research.
A groundbreaking trial reveals that Mounjaro is more effective than Wegovy for weight loss, achieving a 20% reduction over 72 weeks compared to Wegovy's 14%. Discover the implications for obesity treatment!